This trial also found reductions in fasting glucose and fasting insulin, and resulted in a 54% and 76% (depending on the dose) reduction in the annualized incidence rate for the progression to type 2 diabetes among all patients studied [8]. The gene discussed is INS; the disease is type 2 diabetes mellitus.